Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a
mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that
will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3
agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the
adjuvants on the immune response. The investigators will monitor these effects by performing
tests in the laboratory on participants' blood and skin tissue.